Tao Li

Dr. Tao Li


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
XHXiaoyuan Hu
Xiaoyuan Hu
CGChunlei Ge
Chunlei Ge
CHCaixiu Huang
Caixiu Huang
DHDan He
Dan He
XYXiaoxuan Yao
Xiaoxuan Yao
HYHong Yao
Hong Yao
Background: Chimeric antigen receptor T-cell (CAR T) therapy development represents a promising therapeutic strategy for HER2-positive non-small cell lung cancer (NSCLC), a subtype accounting for 1–5% of NSCLC cases. However, the clinical efficacy of CAR T cells remains limited by poor tumor infiltration. Here, we identify NSCLC-specific overexpression of the CXCL13 and CCL20 chemokines within the tumor microenvironment (TME) and develop a dual chemokine receptor strategy to overcome this barrier. Methods: Western blotting and qRT-PCR were used to quantify chemokine receptor expression (CXCR5, CCR6) in NSCLC. Cytotoxicity and antigen recognition sensitivity of CXCR5-CCR6-HER2-CAR T cells against target cells were assessed using in vitro co-culture assays. In vitro proliferation and migration capacities of these engineered T cells were also evaluated. Anti-tumor activity was determined through in vivo animal experiments. Results: We demonstrate for the first time that HER2-targeted CAR T cells co-expressing the chemokine receptors CXCR5 and CCR6 selectively respond to CXCL13 and CCL20, which are highly expressed in the NSCLC TME. This dual chemokine receptor co-expression strategy has not been previously applied to solid tumors. The CXCR5/CCR6 pairing synergistically enhanced the antitumor activity of HER2-CAR T cells in both in vitro and in vivo models. Furthermore, CXCR5 and CCR6 co-expression significantly improved the in vitro cytotoxicity, antigen recognition sensitivity, proliferation, and migration of HER2-CAR T cells. In vivo, this modification enhanced HER2-CAR T cell survival, expansion, and tumor infiltration. Conclusion: CXCR5/CCR6 co-expression establishes a novel therapeutic paradigm for refractory HER2-positive NSCLC. Its modular design facilitates rapid clinical translation and adaptation to other chemokine-defined solid tumors.

12 June 2024 in Heliyon
Verified
Journal Article
Open access
XHXiaoyuan Hu
Xiaoyuan Hu
NWNing Wang
Ning Wang
FGFei Gao
Fei Gao
SGShengyou Ge
Shengyou Ge
MLMei Lin
Mei Lin
YFYuanyong Feng
Yuanyong Feng
Chemerin, as a novel multifunctional adipokine, is proposed to be involved in high cancer risk and mortality. The present study was aimed to evaluate the prognostic value of serum Chemerin and neutrophils in patients with oral squamous cell carcinoma (OSCC). 120 patients with OSCC were included in this prospective cohort study. The levels of serum Chemerin were measured by enzyme-linked immunosorbent assay (ELISA). We also explored the possible effects of Chemerin on neutrophils’ chemokines in OSCC using a real-time PCR, western blotting. Levels of serum Chemerin, neutrophils and NLR were significantly higher among non-survivors compared to survivors of OSCC (both P < 0.05). Higher serum Chemerin levels were associated with advanced TNM stage, lymph node metastasis, differentiation and tumor recurrence (both P < 0.05). Serum Chemerin levels correlated with neutrophils and NLR levels (r = 0.708, r = 0.578, both P < 0.05). Based on ROC analysis, Chemerin + NLR predicted OSCC patient mortality with 81.54 % sensitivity and 87.27 % specificity, with an AUC of 0.8898. In a Kaplan-Meier analysis, high serum Chemerin levels, high neutrophil levels and high NLR levels were associated with shorter overall and disease-free survival (both P < 0.05). A univariate and multivariate Cox regression analysis showed that serum Chemerin and neutrophils were independent risk factors for OSCC. (both P < 0.05). QRT-PCR and western blotting results showed that Chemerin upregulated the expression of chemokines IL-17 and CXCL-5 in neutrophils (both P < 0.05). Our study suggests that measurement of serum Chemerin and neutrophils might be a useful diagnostic and prognostic biomarker for OSCC patients. Chemerin may promote neutrophils infiltration in OSCC through upregulation of chemokines IL17 and CXCL-5.

19 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Nabeel AhmedNabeel Ahmed
Nabeel Ahmed
JJJawaria Jabeen
Jawaria Jabeen
SNSafa Noor
Safa Noor
MRMalja Rehman
Malja Rehman
STSana Tahseen
Sana Tahseen
Zhiwei HuZhiwei Hu
Zhiwei Hu
Background: For almost two decades now, chimeric antigen receptor-natural killer cells (CAR-NK) have been investigated in pre-clinical breast cancer models, yet clinical evidence on efficacy remains scarce. This meta-analysis provides pooled evidence of pre-clinical CAR-NK effectiveness and safety in breast cancer and an overview of current clinical trials to support clinical translation. Methods: Following PRISMA guidelines and a registered protocol (PROSPERO, CRD420251131530), PubMed, Web of Science, and Scopus were searched up to 30 June 2025 for pre-clinical CAR-NK studies in breast cancer. Clinical studies were retrieved from clinicaltrials.gov and the International Clinical Trial Registry Platform (ICTRP) up to 1 March 2026. Pre-clinical studies without in vivo data or non-human CAR-NK cells were excluded. Primary outcomes were tumor burden (ratio of means, ROMs) and survival (median survival ratio, MSR). Data were analyzed in JASP™ and risk of bias (RoB) was assessed using SYRCLE’s tool. Results: Fourteen pre-clinical studies (38 CAR-NK treatment groups targeting EGFR, HER2, tissue factor, CD70, mesothelin, or folate receptor, with peripheral blood as the primary NK source, and a 5–10 million cell dose) and 11 early-phase clinical studies (targeting HER2, TROP2, PD-L1, MUC1, or NKG2D ligands under ongoing investigation) were included. In pooled pre-clinical analysis, CAR-NK significantly reduced tumor burden against untreated and unmodified/mock controls (ROM 0.311 [0.22–0.44] and 0.42 [0.33–0.53], p < 0.001, respectively). Survival was also prolonged significantly (MSR 1.47 [1.15–1.87], p = 0.010 vs. untreated; 1.30 [1.09–1.60], p = 0.007 vs. unmodified/mock NK cells). Subgroup analyses indicated improved efficacy with peripheral blood source and 5–10 M dosing. No treatment-related toxicities were reported. CAR-NK persistence was generally higher than unmodified/mock NK cells. Discussion and Conclusions: Significant heterogeneity was observed in ROM analysis which the multi-level meta-analysis configured as intra-study interventional variability. There was moderate RoB in pre-clinical studies. Published results from clinical trials remain limited, highlighting early stages of investigation. Overall, CAR-NK therapy demonstrated consistent pre-clinical efficacy and safety, supporting further translational and clinical evaluation in breast cancer.

24 July 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
YYYang Yang
Yang Yang
YZYibo Zhu
Yibo Zhu
TYTao Yang
Tao Yang
TLTao Li
Tao Li
YJYuan Ju
Yuan Ju
YLYoufu Luo
Youfu Luo
Unlike other bacterial ClpP systems, mycobacterial ClpP1P2 complex is essential for mycobacterial survival. The functional details of Mycobacterium tuberculosis ( Mtb ) ClpP1P2 remains largely elusive and selectively targeting ClpP of different species is a big challenge. In this work, cediranib was demonstrated to significantly decrease the activity of Mtb ClpP1P2. By solving the crystal structure of cediranib-bound Mtb ClpP1P2, we found that cediranib dysregulates Mtb ClpP1P2 by interfering with handle domain of the equatorial region of Mtb ClpP1, indicating that the inter-ring dynamics are crucial for its function. This finding provides direct evidence for the notion that a conformational switch in the equatorial handle domain is essential for ClpP activity. We also present biochemical data to interpret the distinct interaction pattern and inhibitory properties of cediranib toward Mtb ClpP1P2. These results suggest that the variable handle domain region is responsible for the species-selectivity of cediranib, which suggests the equatorial handle domain as a potential region for screening pathogen-specific ClpP inhibitors.

29 December 2025 in Virology Journal
Verified
Journal Article
Open access
PDF file
YWYao Wang
Yao Wang
CWCuiling Wu
Cuiling Wu
WYWang Yingzhi
Wang Yingzhi
TLTao Li
Tao Li
The recent global outbreak of Monkeypox virus since 2022, particularly outside Africa, has underscored its significant threat to public health. Genomic sur

16 May 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TLTao Li
Tao Li
LLLing Liu
Ling Liu
LLLi Li
Li Li
XYXiaoxuan Yao
Xiaoxuan Yao
XHXiaoyuan Hu
Xiaoyuan Hu
HYHong Yao
Hong Yao
The combination of anti-angiogenesis agents with immune-checkpoint inhibitors is a promising treatment for patients with advanced hepatocellular carcinoma (HCC); however, therapeutic resistance caused by cancer stem cells present in tumor microenvironments remains to be overcome. In this study, we report for the first time that the Kringle 1 domain of human hepatocyte growth-factor α chain (HGFK1), a previously described anti-angiogenesis peptide, repressed the sub-population of CD90+ cancer stem cells (CSCs) and promoted their differentiation and chemotherapy sensitivity mainly through downregulation of pre-Met protein expression and inhibition of Wnt/β-catenin and Notch pathways. Furthermore, we showed that the i.p. injection of PH1 (a tumor-targeted and biodegradable co-polymer), medicated plasmids encoding Endostatin (pEndo), HGFK1 genes (pEndo), and a combination of 50% pEndo + 50% pHGFK1 all significantly suppressed tumor growth and prolonged the survival of the HCC-bearing mice. Importantly, the combined treatment produced a potent synergistic effect, with 25% of the mice showing the complete clearance of the tumor via a reduction in the microvessel density (MVD) and the number of CD90+ CSCs in the tumor tissues. These results suggest for the first time that HGFK1 inhibits the CSCs of HCC. Furthermore, the combination of two broad-spectrum anti-angiogenic factors, Endo and HGFK1, is the optimal strategy for the development of effective anti-HCC drugs.